Physician profile
Gregory A Nikolaidis
NPI 1033181813
$57,751.87
in general payments reported to CMS, 2019-2025
18 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $635 · 2021: $6,502 · 2022: $1,802 · 2023: $9,102 · 2024: $3,871 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,029 · Food and Beverage: $6,281 · Travel and Lodging: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,029.34 |
| Food and Beverage | $6,281.29 |
| Travel and Lodging | $445.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31,124.05 | 2019-2022 | |
| Abbvie INC. | $11,772.40 | 2021-2025 | |
| Merz North America, INC. | $11,084.76 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $2,196.96 | 2019-2025 | Dysport, Aklief |
| Revance Therapeutics, INC. | $656.11 | 2024-2025 | Daxxify, Daxi |
| Abbott Laboratories | $285.42 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Vyne Pharmaceuticals INC. | $174.27 | 2021 | |
| Leo Pharma INC. | $138.11 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $91.17 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $44.89 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $43.57 | 2022-2023 | Libtayo |
| Sun Pharmaceutical Industries INC. | $31.44 | 2021-2024 | |
| Lilly USA, LLC | $22.89 | 2023 | Olumiant, Taltz |
| Mentor Worldwide LLC | $21.53 | 2019 | |
| Biofrontera INC. | $19.77 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.47 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.69 | 2021 | |
| Genzyme Corporation | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Nikolaidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.